ACE2 and COVID-19: There is one Phase I/II clinical trial testing repurposing ACE2 (originally for treating pulmonary arterial hypertension and acute respiratory distress syndrome) as COVID-19 treatment (Clinical-Trials.gov identifier: NCT04335136).